

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2020/216379 A1**

(43) International Publication Date  
29 October 2020 (29.10.2020)

(51) International Patent Classification:

*C07K 16/28* (2006.01) *G01N 33/68* (2006.01)  
*C12N 15/13* (2006.01) *A61K 39/395* (2006.01)  
*C12P 21/02* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

(21) International Application Number:

PCT/CN2020/087019

(22) International Filing Date:

26 April 2020 (26.04.2020)

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2019/084468

26 April 2019 (26.04.2019) CN

(71) Applicant: **I-MAB** [CN/CN]; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN).

(72) Inventors: **FANG, Lei**; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN). **YANG, Yuanyuan**; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN). **WANG, Zhengyi**; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN). **GUO, Bingshi**; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN).

(74) Agent: **SHANGHAI BESHINING LAW OFFICE**; 21st Floor SFECO Mansion, 681 Xiaomujiao Road, Shanghai 200032 (CN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: HUMAN PD-L1 ANTIBODIES

(57) Abstract: Provided are full human anti-PD-L1 antibodies or fragments thereof. In various examples, the antibodies or fragments thereof include a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 which are selected from sequence groups of SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO: 80-88 and SEQ ID NO: 89-102, respectively, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

